JPWO2021207335A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021207335A5
JPWO2021207335A5 JP2022561040A JP2022561040A JPWO2021207335A5 JP WO2021207335 A5 JPWO2021207335 A5 JP WO2021207335A5 JP 2022561040 A JP2022561040 A JP 2022561040A JP 2022561040 A JP2022561040 A JP 2022561040A JP WO2021207335 A5 JPWO2021207335 A5 JP WO2021207335A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical combination
menin
combination according
cyp3a4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522166A5 (https=
JP2023522166A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/026141 external-priority patent/WO2021207335A1/en
Publication of JP2023522166A publication Critical patent/JP2023522166A/ja
Publication of JP2023522166A5 publication Critical patent/JP2023522166A5/ja
Publication of JPWO2021207335A5 publication Critical patent/JPWO2021207335A5/ja
Pending legal-status Critical Current

Links

JP2022561040A 2020-04-07 2021-04-07 メニン阻害剤とcyp3a4阻害剤との組合せ、およびその使用方法 Pending JP2023522166A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006574P 2020-04-07 2020-04-07
US63/006,574 2020-04-07
PCT/US2021/026141 WO2021207335A1 (en) 2020-04-07 2021-04-07 Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023522166A JP2023522166A (ja) 2023-05-29
JP2023522166A5 JP2023522166A5 (https=) 2024-04-16
JPWO2021207335A5 true JPWO2021207335A5 (https=) 2024-04-16

Family

ID=78023861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561040A Pending JP2023522166A (ja) 2020-04-07 2021-04-07 メニン阻害剤とcyp3a4阻害剤との組合せ、およびその使用方法

Country Status (10)

Country Link
US (1) US12564590B2 (https=)
EP (1) EP4132932A4 (https=)
JP (1) JP2023522166A (https=)
KR (1) KR20230007359A (https=)
CN (3) CN120393026A (https=)
AU (1) AU2021252552A1 (https=)
CA (1) CA3178691A1 (https=)
IL (1) IL297039A (https=)
MX (1) MX2022012471A (https=)
WO (1) WO2021207335A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ.ベー. 置換直鎖スピロ誘導体
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
WO2023150635A1 (en) * 2022-02-04 2023-08-10 Kura Oncology, Inc. Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
JP2025516558A (ja) * 2022-05-09 2025-05-30 シンダックス ファーマシューティカルズ, インコーポレイテッド 癌治療のためのメニン-mll阻害剤
CN120456907A (zh) * 2022-11-02 2025-08-08 库拉肿瘤学公司 急性白血病的治疗方法
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
WO2025106862A1 (en) * 2023-11-17 2025-05-22 Kura Oncology, Inc. Methods of treating kit positive cancers with a menin inhibitor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5820915A (en) 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en) 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5990154A (en) 1997-05-30 1999-11-23 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds and citrus extract
US6063809A (en) 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US6248776B1 (en) 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US5993887A (en) 1998-06-29 1999-11-30 Bioavailability Systems, L.L.C. Safe citrus juice and process for preparation
WO2004037827A1 (en) 2000-10-20 2004-05-06 Bioavailability Systems, Llc Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1732891A4 (en) 2004-03-11 2009-05-06 Sequoia Pharmaceuticals Inc RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES
EP2422781A1 (en) 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
KR20180084153A (ko) 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型c-kit的方法
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
US9458124B2 (en) 2013-02-06 2016-10-04 Wayne State University Substituted pyran derivatives
KR20150130389A (ko) 2013-03-13 2015-11-23 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
WO2015108940A2 (en) 2014-01-14 2015-07-23 The Trustees Of The University Of Pennsylvania Tailored combinatorial epigenetic therapies for p53 gain-of-function tumors
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2016025635A2 (en) * 2014-08-13 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
EP4643952A3 (en) 2016-01-26 2026-01-14 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3805215A1 (en) * 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
US10899758B2 (en) 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
KR20200101389A (ko) 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP2021519785A (ja) 2018-03-30 2021-08-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン化合物
AU2019337547A1 (en) 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
EP3856173A4 (en) 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
AU2022271791A1 (en) 2021-05-12 2024-01-04 Board Of Regents, The University Of Texas System Combinations for treatment of cancer
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CN118234497A (zh) 2021-12-15 2024-06-21 丹娜-法伯癌症研究所 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)
TW202525797A (zh) 2023-08-28 2025-07-01 美商錫達斯醫藥股份有限公司 作為menin-mll交互作用之抑制劑的芳基醚類似物

Similar Documents

Publication Publication Date Title
JP2023002662A5 (https=)
JP2022022264A5 (https=)
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
KR101390144B1 (ko) 염증성 장질환 치료제
CN102573852A (zh) 用于治疗ibd的药物组合物
EP3027183B1 (en) Selective at2 receptor agonists for use in treatment of cachexia
Seiler et al. Adverse event management of oral mucositis in patients with breast cancer
JPWO2021207335A5 (https=)
JP2015517523A5 (https=)
JP2019533660A5 (https=)
CN109985237A (zh) 一种治疗结直肠癌的药物组合物及其应用
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
JPWO2020257671A5 (https=)
US11628163B2 (en) 1-piperidinepropionic acid for treating a fibrosing disease
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2022177119A5 (https=)
WO2024249875A1 (en) Combinations of estrogen receptor degraders and akt inhibitors
RU2721409C1 (ru) Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови
ES2554332T3 (es) Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40
CN105079012B (zh) 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用
JPWO2022106711A5 (https=)
JPWO2022218956A5 (https=)
CN111494371B (zh) Pyr3的用途
CN104983728A (zh) 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用
CN104510854A (zh) 一种治疗妇女痛经的中药组合物及其用途